Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 5/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | STK4 | Q13043 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.46 |
| ▸ | GAK | O14976 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14369457 | 0.85 | PDE4B (0.44) | PDE4BGAAMAPTEGFR | |
| SCHEMBL4904273 | 0.76 | PDE4B (0.56) | PDE4BRAF1MAP2K1KDM4EGAA | |
| SCHEMBL6380922 | 0.74 | PDE4B (0.71) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL1893705 | 0.74 | PDE4B (0.71) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL3873667 | 0.74 | PDE4B (0.58) | PDE4BRAF1MAP2K1CDK1KDR | |
| SCHEMBL6382347 | 0.73 | EGFR (0.70) | PDE4BRAF1MAP2K1STK4EGFR | |
| Hydrochloric Acid SCHEMBL6381171 | 0.72 | EGFR (0.70) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL1892801 | 0.71 | EGFR (0.71) | PDE4BRAF1MAP2K1STK4EGFR | |
| SCHEMBL6381476 | 0.70 | EGFR (0.75) | PDE4BRAF1MAP2K1EGFRERBB2 | |
| SCHEMBL6380260 | 0.70 | EGFR (0.77) | PDE4BRAF1MAP2K1STK4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598263-B2 | Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AG (DE) | 2009-10-06 | — | — | US | claimed |
| US-20080108627-A1 | CYANOQUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | BAYER SCHERING PHARMA AG (DE) | 2008-05-08 | — | — | US | claimed |
| US-7598263-B2 | Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AG (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598263-B2 | Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AG (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598263-B2 | Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them | BAYER SCHERING PHARMA AG (DE) | 2009-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108627-A1 | CYANOQUINOLINE DERIVATIVES, THEIR PREPARATION, THEIR USE, AND MEDICAMENTS COMPRISING THEM | RECQL, KCNQ1, KCNQ2 | PDE4B 1219/4885RAF1 2464/4885MAP2K1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.